149 related articles for article (PubMed ID: 8510013)
1. The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat.
Pendley CE; Fitzpatrick LR; Ewing RW; Molino BF; Martin GE
J Pharmacol Exp Ther; 1993 Jun; 265(3):1348-54. PubMed ID: 8510013
[TBL] [Abstract][Full Text] [Related]
2. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist.
Makovec F; Revel L; Letari O; Mennuni L; Impicciatore M
Eur J Pharmacol; 1999 Mar; 369(1):81-90. PubMed ID: 10204685
[TBL] [Abstract][Full Text] [Related]
3. RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat.
Pendley CE; Fitzpatrick LR; Capolino AJ; Davis MA; Esterline NJ; Jakubowska A; Bertrand P; Guyon C; Dubroeucq MC; Martin GE
J Pharmacol Exp Ther; 1995 Jun; 273(3):1015-22. PubMed ID: 7791071
[TBL] [Abstract][Full Text] [Related]
4. L-365,260, a potent CCK-B/gastrin receptor antagonist, suppresses gastric acid secretion induced by histamine and bethanechol as well as pentagastrin in rats.
Nishida A; Yuki H; Tsutsumi R; Miyata K; Kamato T; Ito H; Yamano M; Honda K
Jpn J Pharmacol; 1992 Feb; 58(2):137-45. PubMed ID: 1354760
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
[TBL] [Abstract][Full Text] [Related]
6. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo.
Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD
Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084
[TBL] [Abstract][Full Text] [Related]
7. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.
Takinami Y; Yuki H; Nishida A; Akuzawa S; Uchida A; Takemoto Y; Ohta M; Satoh M; Semple G; Miyata K
Aliment Pharmacol Ther; 1997 Feb; 11(1):113-20. PubMed ID: 9042983
[TBL] [Abstract][Full Text] [Related]
8. Effects of S-0509, a novel CCKB/gastrin receptor antagonist, on acid secretion and experimental duodenal ulcers in rats.
Takeuchi K; Hirata T; Yamamoto H; Kunikata T; Ishikawa M; Ishihara Y
Aliment Pharmacol Ther; 1999 Jan; 13(1):87-96. PubMed ID: 9892884
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of gastrin- and histamine-stimulated gastric acid secretion by gastrin and cholecystokinin antagonists in the rat.
Hirst BH; Elliott KJ; Ryder H; Szelke M
Aliment Pharmacol Ther; 1991 Feb; 5(1):31-9. PubMed ID: 1932479
[TBL] [Abstract][Full Text] [Related]
10. Effects of N-(3-[3-(1-piperidinylmethyl)phenoxy]propyl)-acetoxyacetamide hydrochloride (TZU-0460), a histamine H2-receptor antagonist, on gastric acid secretion and ulcer formation.
Tarutani M; Sakuma H; Shiratsuchi K; Mieda M
Arzneimittelforschung; 1985; 35(5):844-8. PubMed ID: 2862875
[TBL] [Abstract][Full Text] [Related]
11. YM022, a potent and selective gastrin/CCK-B receptor antagonist, inhibits peptone meal-induced gastric acid secretion in Heidenhain pouch dogs.
Yuki H; Nishida A; Miyake A; Ito H; Akuzawa S; Takinami Y; Takemoto Y; Miyata K
Dig Dis Sci; 1997 Apr; 42(4):707-14. PubMed ID: 9125636
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the variation in the action of L-365,260 at CCKB/gastrin receptors in rat, guinea-pig and mouse isolated gastric tissue assays.
Roberts SP; Harper EA; Watt GF; Gerskowitch VP; Hull RA; Shankley NP; Black JW
Br J Pharmacol; 1996 Aug; 118(7):1779-89. PubMed ID: 8842444
[TBL] [Abstract][Full Text] [Related]
13. The effect of CCKB/gastrin antagonists on stimulated gastric acid secretion in the anaesthetized rat.
Hayward NJ; Harding M; Lloyd SA; McKnight AT; Hughes J; Woodruff GN
Br J Pharmacol; 1991 Dec; 104(4):973-7. PubMed ID: 1687371
[TBL] [Abstract][Full Text] [Related]
14. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.
Nishida A; Takinami Y; Yuki H; Kobayashi A; Akuzawa S; Kamato T; Ito H; Yamano M; Nagakura Y; Miyata K
J Pharmacol Exp Ther; 1994 Sep; 270(3):1256-61. PubMed ID: 7932178
[TBL] [Abstract][Full Text] [Related]
15. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260.
Lotti VJ; Chang RS
Eur J Pharmacol; 1989 Mar; 162(2):273-80. PubMed ID: 2721567
[TBL] [Abstract][Full Text] [Related]
16. CCK-B (gastrin) receptor regulates gastric histamine release and acid secretion.
Sandvik AK; Waldum HL
Am J Physiol; 1991 Jun; 260(6 Pt 1):G925-8. PubMed ID: 1711780
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a significant role of gastrin in cysteamine-induced hypersecretion of gastric acid.
Shiratori K; Shimizu K; Ikeda M; Watanabe S; Hayashi N
J Clin Gastroenterol; 1997; 25 Suppl 1():S84-8. PubMed ID: 9479631
[TBL] [Abstract][Full Text] [Related]
18. Different effects of CCK antagonists on gastric-acid response to CCK and pentagastrin.
Corwin RL; Smith GP
Peptides; 1993; 14(2):253-7. PubMed ID: 8483804
[TBL] [Abstract][Full Text] [Related]
19. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
[TBL] [Abstract][Full Text] [Related]
20. Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat.
Schmassmann A; Garner A; Flogerzi B; Hasan MY; Sanner M; Varga L; Halter F
Gut; 1994 Feb; 35(2):270-4. PubMed ID: 8307482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
